The emerging role of plasma lipidomics in cardiovascular drug discovery

Bibliography

• Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104(23):2855-64
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Brewer HB, Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006;354(1):1253-63
   PubMedGoogle Scholar
• Nissen SE, Tardif JC, Nicholls SJ, Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356(13):1304-16
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299(13):1561-73
   PubMed Web of Science ®Google Scholar
• Griffiths WJ, Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem Soc Rev 2009;38(7):1882-96
   PubMed Web of Science ®Google Scholar
• Gross RW, Han X. Lipidomics at the interface of structure and function in systems biology. Chem Biol 2011;18(3):284-91
   PubMed Web of Science ®Google Scholar
• Brugger B, Erben G, Sandhoff R, Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. Proc Natl Acad Sci USA 1997;94(6):2339-44
   PubMed Web of Science ®Google Scholar
• Sullards MC, Merrill AH Jr. Analysis of sphingosine 1-phosphate, ceramides, and other bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Sci STKE 2001;2001(67):p11
   Google Scholar
• Fenn JB, Mann M, Meng CK, Electrospray ionization for mass spectrometry of large biomolecules. Science 1989;246(4926):64-71
   PubMed Web of Science ®Google Scholar
• Thomas A, Lenglet S, Chaurand P, Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics. Thromb Haemost 2011;106(1):20-33
   PubMed Web of Science ®Google Scholar
• Wenk MR. The emerging field of lipidomics. Nat rev Drug discov 2005;4(7):594-610
   PubMed Web of Science ®Google Scholar
• Harkewicz R, Dennis EA. Applications of mass spectrometry to lipids and membranes. Annu Rev Biochem 2011;80:301-25
   PubMed Web of Science ®Google Scholar
• Puolitaival SM, Burnum KE, Cornett DS, Caprioli RM. Solvent-free matrix dry-coating for MALDI imaging of phospholipids. J Am Soc Mass Spectrom 2008;19(6):882-6
   PubMed Web of Science ®Google Scholar
• Fu R, Cross TA. Solid-state nuclear magnetic resonance investigation of protein and polypeptide structure. Annu Rev Biophys Biomol Struct 1999;28:235-68
   PubMedGoogle Scholar
• Gawrisch K, Eldho NV, Polozov IV. Novel NMR tools to study structure and dynamics of biomembranes. Chem Phys Lipids 2002;116(1-2):135-51
   PubMed Web of Science ®Google Scholar
• Chaurand P, Schwartz SA, Reyzer ML, Caprioli RM. Imaging mass spectrometry: principles and potentials. Toxicol Pathol 2005;33(1):92-101
   PubMed Web of Science ®Google Scholar
• Taira S, Sugiura Y, Moritake S, Nanoparticle-assisted laser desorption/ionization based mass imaging with cellular resolution. Anal Chem 2008;80(12):4761-6
   PubMed Web of Science ®Google Scholar
• Sugiura Y, Konishi Y, Zaima N, Visualization of the cell-selective distribution of PUFA-containing phosphatidylcholines in mouse brain by imaging mass spectrometry. J Lipid Res 2009;50(9):1776-88
   PubMed Web of Science ®Google Scholar
• Garrett TJ, Yost RA. Tandem mass spectrometric methods for phospholipid analysis from brain tissue. Methods Mol Biol 2010;656:209-30
   PubMedGoogle Scholar
• Groseclose MR, Massion PP, Chaurand P, Caprioli RM. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008;8(18):3715-24
   PubMed Web of Science ®Google Scholar
• Stauber J, Lemaire R, Franck J, MALDI imaging of formalin-fixed paraffin-embedded tissues: application to model animals of Parkinson disease for biomarker hunting. J Proteome Res 2008;7(3):969-78
   PubMed Web of Science ®Google Scholar
• Wenk MR. Lipidomics: new tools and applications. Cell 2010;143(6):888-95
   PubMed Web of Science ®Google Scholar
• Sysi-Aho M, Vehtari A, Velagapudi VR, Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles. Bioinformatics 2007;23(13):i519-28
   PubMed Web of Science ®Google Scholar
• Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987;257(16):2176-80
   PubMed Web of Science ®Google Scholar
• Martin MJ, Hulley SB, Browner WS, Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986;2(8513):933-6
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, Department of Veterans Affairs HDL Intervention Trial Study Group. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75(17):1196-201
   PubMed Web of Science ®Google Scholar
• Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001;88(12A):9N-13N
   PubMedGoogle Scholar
• Shepherd J, Cobbe SM, Ford I, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349-57
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I, Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297(5):499-508
   PubMed Web of Science ®Google Scholar
• Wiesner P, Leidl K, Boettcher A, Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009;50(3):574-85
   PubMed Web of Science ®Google Scholar
• Hansel B, Giral P, Nobecourt E, Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004;89(10):4963-71
   PubMed Web of Science ®Google Scholar
• Kontush A, Therond P, Zerrad A, Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007;27(8):1843-9
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Lipidomics as a tool for the study of lipoprotein metabolism. Curr Atheroscler Rep 2010;12(3):194-201
   PubMed Web of Science ®Google Scholar
• Yetukuri L, Soderlund S, Koivuniemi A, Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res 2010;51(8):2341-51
   PubMed Web of Science ®Google Scholar
• Hicks AA, Pramstaller PP, Johansson A, Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet 2009;5(10):e1000672
   PubMed Web of Science ®Google Scholar
• Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23(10):1881-8
   PubMed Web of Science ®Google Scholar
• Catalano G, Julia Z, Frisdal E, Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009;29(2):268-75
   PubMed Web of Science ®Google Scholar
• Zerrad-Saadi A, Therond P, Chantepie S, HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2009;29(12):2169-75
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-22
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hsu A, Wolski K, Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010;55(21):2399-407
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291(9):1071-80
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295(13):1556-65
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Borgman M, Nissen SE, Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin 2011;27(6):1119-29
   PubMed Web of Science ®Google Scholar
• Bergheanu SC, Reijmers T, Zwinderman AH, Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 2008;24(9):2477-87
   PubMed Web of Science ®Google Scholar
• Smith EB. Intimal and medial lipids in human aortas. Lancet 1960;1(7128):799-803
   PubMedGoogle Scholar
• Noel C, Marcel YL, Davignon J. Plasma phospholipids in the different types of primary hyperlipoproteinemia. J Lab Clin Med 1972;79(4):611-21
   PubMedGoogle Scholar
• Schissel SL, Jiang X, Tweedie-Hardman J, Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998;273(5):2738-46
   PubMed Web of Science ®Google Scholar
• Jiang XC, Paultre F, Pearson TA, Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000;20(12):2614-18
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681-90
   PubMed Web of Science ®Google Scholar
• Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010;95(5):2015-22
   PubMed Web of Science ®Google Scholar
• Paiva H, Thelen KM, Van Coster R, High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78(1):60-8
   PubMed Web of Science ®Google Scholar
• Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011;365(4):285-7
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Katajamaa M, Paiva H, A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006;1:e97
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Janis MT, Oresic M. Lipidomics-based safety biomarkers for lipid-lowering treatments. Angiology 2008;59(2 Suppl):65S-8S
   PubMedGoogle Scholar
• Armitage J, Bowman L, Wallendszus K, Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376(9753):1658-69
   PubMed Web of Science ®Google Scholar
• Pietilainen KH, Sysi-Aho M, Rissanen A, Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects–a monozygotic twin study. PLoS ONE 2007;2(2):e218
   PubMedGoogle Scholar
• de Mello VD, Lankinen M, Schwab U, Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabtologia 2009;52(12):2612-15
   PubMed Web of Science ®Google Scholar
• Puri P, Wiest MM, Cheung O, The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50(6):1827-38
   PubMed Web of Science ®Google Scholar
• Graessler J, Schwudke D, Schwarz PE, Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS ONE 2009;4(7):e6261
   PubMed Web of Science ®Google Scholar
• Guerrera IC, Astarita G, Jais JP, A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PLoS ONE 2009;4(11):e7735
   PubMedGoogle Scholar
• Meikle PJ, Wong G, Tsorotes D, Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol 2011;31(11):2723-32
   PubMed Web of Science ®Google Scholar
• Bayturan O, Tuzcu EM, Lavoie A, The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010;170(5):478-84
   PubMed Web of Science ®Google Scholar